Bonmax Pth Customized Autopen

The Bonmax Pth Customized Autopen is an advanced pharmaceutical solution designed for the effective management of severe osteoporosis. This product utilizes Teriparatide, a recombinant human parathyroid hormone (rhPTH(1-34)) analogue, delivered via a pre-filled, customized autopen device, ensuring precise and consistent dosing for healthcare professionals and trained patients.

Teriparatide functions as an anabolic agent, actively stimulating osteoblasts, the bone-forming cells. This mechanism promotes the generation of new bone tissue, leading to a significant increase in bone mineral density (BMD) and enhanced bone strength. Unlike anti-resorptive therapies, Bonmax Pth directly contributes to bone formation, addressing the underlying pathology of bone fragility.

This therapeutic agent is clinically indicated for the treatment of severe osteoporosis in diverse patient populations, including men and postmenopausal women who are at a high risk of fractures. It is also a valuable option for patients suffering from glucocorticoid-induced osteoporosis, providing a targeted approach to rebuild bone mass and reduce the incidence of debilitating fractures.

Key Features : 

Contains Teriparatide, a recombinant human parathyroid hormone (rhPTH(1-34)) analogue
Stimulates new bone formation by activating osteoblasts
Increases bone mineral density (BMD) and improves bone strength
Reduces the risk of vertebral and non-vertebral fractures
Pre-filled, disposable autopen device for subcutaneous injection
Designed for predictable dosing accuracy and ease of handling
Indicated for severe osteoporosis in men and postmenopausal women at high fracture risk
Also effective for glucocorticoid-induced osteoporosis